<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03139305</url>
  </required_header>
  <id_info>
    <org_study_id>TRIMDFH 954476</org_study_id>
    <nct_id>NCT03139305</nct_id>
  </id_info>
  <brief_title>Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects</brief_title>
  <acronym>GIO B</acronym>
  <official_title>Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to examine the effect of prolonged (72 hour) administration
      of glucagon compared to placebo on energy expenditure in healthy, non-diabetic, obese
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 4, 2017</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of continuous IV infusion of glucagon versus placebo</measure>
    <time_frame>72 hours</time_frame>
    <description>A nausea questionnaire will be administered to measure overall nausea intensity. Nausea will be graded from 0-5, with 0 indicating no nausea, and 5 indicating excruciating nausea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of continuous IV infusion of glucagon versus placebo</measure>
    <time_frame>72 hours</time_frame>
    <description>Overall well-being will be measured by administering a questionnaire with a scale from none to severe.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Glucagon Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucagon High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>Low dose intravenous infusion for 72 hours at 12.5 ng/kg/min</description>
    <arm_group_label>Glucagon Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucagon</intervention_name>
    <description>High dose intravenous infusion for 72 hours at 25 ng/kg/min</description>
    <arm_group_label>Glucagon High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion of saline for 72 hours</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-55 years, inclusive.

          -  Body Mass Index (BMI) ≥27 to ≤45 kg/m2 and body weight &lt;450 lbs.

          -  Stable body weight for 3 months (self-reported loss/gain &lt;5%).

          -  Judged to be non-diabetic per the American Diabetes Association guidelines:

               1. fasting plasma glucose &lt;126 mg/dL [7.0 mmol/L] and

               2. HbA1c &lt;6.5% [48 mmol/mol]) and

               3. in good health on the basis of medical history, physical examination (PE),
                  electrocardiogram (ECG), and normal laboratory values obtained from Screening
                  visit labs.

          -  Understands the procedures and agrees to participate in the study program by giving
             written informed consent, and is willing to comply with the trial restrictions.

          -  Willing to avoid alcohol consumption for 48 hours prior to the inpatient study visit.

          -  Willing to avoid consumption of caffeine and caffeinated beverages for 24 hours prior
             to the inpatient study visit.

          -  Willing to avoid strenuous physical activity for 72 hours prior to the inpatient study
             visit.

        Exclusion Criteria

          -  Treatment with any medication known to significantly impact body weight or energy
             metabolism (e.g., weight loss medications, atypical antipsychotics) within 3 months
             prior to screening except for stable physiological hormone replacement therapy (i.e.,
             thyroid hormone, estrogen).

          -  Treatment with a selective serotonin reuptake inhibitor, a medication for depression
             or apomorphine within one week prior to screening due to interaction with Zofran.

          -  History of bariatric surgery.

          -  Current liver, renal, pulmonary, cardiac, oncologic, metabolic, gastrointestinal, or
             hematologic disease which the Investigator believes is clinically significant,
             including:

             a. Liver disease or liver injury as indicated by abnormal liver function tests
             (aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, serum
             bilirubin) &gt;3 × upper limit of normal (ULN), or history of hepatic cirrhosis.

          -  Impaired renal function as indicated by an estimated glomerular filtration rate (eGFR)
             &lt;60 mL/min or urine albumin-to-creatinine ratio &gt;35 mg/mmol.

          -  Significant cardiovascular disease, including Class III or greater congestive heart
             failure (CHF), coronary artery disease, second degree or greater heart block, or
             clinically significant arrhythmias; baseline second degree or greater heart block or
             prolonged QT syndrome (QTc interval ≥470 msec); or any major cardiovascular event
             within the last 3 years (including myocardial infarction [MI], transient ischemic
             attack, cerebrovascular accident [CVA], angina, and hospitalization due to
             CHF,transient ischemic attack, and CVA).

          -  Metabolic, or other endocrine disorders, including diagnosis of type 1 or type 2
             diabetes mellitus [HbA1c ≥6.5%]), inadequately treated hyperthyroidism (thyroid
             stimulating hormone [TSH] below normal range) or hypothyroidism (TSH &gt;ULN &lt;10 U/mL and
             symptomatic or TSH &gt;10 U/mL), Cushing's disease/syndrome, Addison's disease,
             hypogonadism, or genetic disorders linked to obesity.

          -  History of irritable bowel disease, recurrent nausea, or vomiting.

          -  Anemia (hemoglobin &lt;12 g/dL in males, &lt;11 g/dL in females).

          -  History of dyslipidemia: Fasting triglycerides (TG) &gt;500 mg/dL and low-density
             lipoproteins (LDL) &gt;250 mg/dL.

          -  Self-reported history of infection with hepatitis B virus (HBV), hepatitis C virus
             (HCV), or human immunodeficiency virus (HIV).

          -  History of recurrent sleep disturbances and/or prone to sleep disturbances based on
             lifestyle or employment (e.g., variable work schedule, overnight shift work, etc.).

          -  Diagnosis of sleep apnea with or without use of continuous positive airway
             pressure/BiPAP/AutoPAP.

          -  Major surgery within 3 months prior to screening.

          -  Blood donation within 4 weeks prior to screening.

          -  Participation in another investigational trial within 4 weeks prior to screening. The
             4 week window will be derived from the date of the last trial medication and/or blood
             collection in a previous trial and/or adverse event (AE) related to trial drug
             screening of the current trial.

          -  Use of illicit drugs or nicotine-containing products within 3 months prior to
             screening.

          -  Poor intravenous (IV) access.

          -  Blood pressure &lt;100/50 mmHg or ≥160/100 mmHg during screening.

          -  Heart rate ≥100 bpm during screening.

          -  Fasting plasma glucose &lt;60 mg/dL or ≥126 mg/dL during screening.

          -  Female subjects who are, or intend to become, pregnant during the course of this
             study, are currently breastfeeding, or women of child-bearing potential (WOCBP) who
             refuse to use at least one method of birth control (oral contraceptives, intrauterine
             device, implanted or injectable contraceptives, abstinence).

          -  Translational Research Institute for Metabolism and Diabetes (TRI-MD) staff member or
             immediate relative of TRI-MD staff members directly involved

          -  History of any illness or condition that, in the opinion of the study investigator,
             might confound the results of the study or poses an additional risk to the subject by
             study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Quianna Stokes-Washington</last_name>
    <phone>407-303-3688</phone>
    <email>tri@flhosp.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quianna Stokes-Washington</last_name>
      <phone>407-303-3688</phone>
      <email>tri@flhosp.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tri-md.org</url>
    <description>Translational Research Institute for Metabolism and Diabetes</description>
  </link>
  <reference>
    <citation>Arafat AM, Kaczmarek P, Skrzypski M, Pruszyńska-Oszmalek E, Kołodziejski P, Szczepankiewicz D, Sassek M, Wojciechowicz T, Wiedenmann B, Pfeiffer AF, Nowak KW, Strowski MZ. Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia. 2013 Mar;56(3):588-97. doi: 10.1007/s00125-012-2803-y. Epub 2012 Dec 22.</citation>
    <PMID>23262585</PMID>
  </reference>
  <reference>
    <citation>Astrup A, Rössner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M, Madsen J, Rasmussen MF, Lean ME; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet. 2009 Nov 7;374(9701):1606-16. doi: 10.1016/S0140-6736(09)61375-1. Epub 2009 Oct 23. Erratum in: Lancet. 2010 Mar 20;375(9719):984.</citation>
    <PMID>19853906</PMID>
  </reference>
  <reference>
    <citation>Calles-Escandón J. Insulin dissociates hepatic glucose cycling and glucagon-induced thermogenesis in man. Metabolism. 1994 Aug;43(8):1000-5.</citation>
    <PMID>8052138</PMID>
  </reference>
  <reference>
    <citation>Cegla J, Troke RC, Jones B, Tharakan G, Kenkre J, McCullough KA, Lim CT, Parvizi N, Hussein M, Chambers ES, Minnion J, Cuenco J, Ghatei MA, Meeran K, Tan TM, Bloom SR. Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes. 2014 Nov;63(11):3711-20. doi: 10.2337/db14-0242. Epub 2014 Jun 17.</citation>
    <PMID>24939425</PMID>
  </reference>
  <reference>
    <citation>Cryer PE. Minireview: Glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology. 2012 Mar;153(3):1039-48. doi: 10.1210/en.2011-1499. Epub 2011 Dec 13. Review.</citation>
    <PMID>22166985</PMID>
  </reference>
  <reference>
    <citation>Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A. The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord. 2000 Mar;24(3):288-98.</citation>
    <PMID>10757621</PMID>
  </reference>
  <reference>
    <citation>Kim J, Heshka S, Gallagher D, Kotler DP, Mayer L, Albu J, Shen W, Freda PU, Heymsfield SB. Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults. J Appl Physiol (1985). 2004 Aug;97(2):655-60. Epub 2004 Apr 16.</citation>
    <PMID>15090482</PMID>
  </reference>
  <reference>
    <citation>Melzack R, Rosberger Z, Hollingsworth ML, Thirlwell M. New approaches to measuring nausea. CMAJ. 1985 Oct 15;133(8):755-8, 761.</citation>
    <PMID>4042058</PMID>
  </reference>
  <reference>
    <citation>Miyoshi H, Shulman GI, Peters EJ, Wolfe MH, Elahi D, Wolfe RR. Hormonal control of substrate cycling in humans. J Clin Invest. 1988 May;81(5):1545-55.</citation>
    <PMID>3284915</PMID>
  </reference>
  <reference>
    <citation>Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J Clin Endocrinol Metab. 1987 May;64(5):896-901.</citation>
    <PMID>2881943</PMID>
  </reference>
  <reference>
    <citation>Salem V, Izzi-Engbeaya C, Coello C, Thomas DB, Chambers ES, Comninos AN, Buckley A, Win Z, Al-Nahhas A, Rabiner EA, Gunn RN, Budge H, Symonds ME, Bloom SR, Tan TM, Dhillo WS. Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. Diabetes Obes Metab. 2016 Jan;18(1):72-81. doi: 10.1111/dom.12585. Epub 2015 Nov 20.</citation>
    <PMID>26434748</PMID>
  </reference>
  <reference>
    <citation>SCHULMAN JL, CARLETON JL, WHITNEY G, WHITEHORN JC. Effect of glucagon on food intake and body weight in man. J Appl Physiol. 1957 Nov;11(3):419-21.</citation>
    <PMID>13480952</PMID>
  </reference>
  <reference>
    <citation>Tan TM, Field BC, McCullough KA, Troke RC, Chambers ES, Salem V, Gonzalez Maffe J, Baynes KC, De Silva A, Viardot A, Alsafi A, Frost GS, Ghatei MA, Bloom SR. Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia. Diabetes. 2013 Apr;62(4):1131-8. doi: 10.2337/db12-0797. Epub 2012 Dec 17.</citation>
    <PMID>23248172</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucagon</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

